参考文献/References:
1 Hegodus L, Bonnema SJ, Bennedbsek FN, et al. Management of simple nodular goiter:current status and future perspectives.Endocr Rev, 2003, 24(1):102-132.
2 Meller J, Siefker U, Hamsnn A, et al. Incidence of radioiodine induced Graves’ disease in patients with multinodular toxic goiter.Exp Clin Endocrinol Diabetes, 2006, 114(5):235-239.
3 Wallaschofsld H, Muller D, Georgi P, et al. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res, 2002, 34(1):36-39.
4 Cseke B, Balazs C. Development of Basedows disease after radioiodine therapy for nodular goiter. Orv Hetil, 2003, 144(47):2327-2329.
5 Schmidt M, Gorbauch E, Dietlein M, et al. Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid, 2006, 16(3):281-288.
6 Dunkelmann S, Wolf R, Koch A, et al. Incidence of radiationinduced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging, 2004,31(10):1428-1434.
7 Nygoard B, Knudsen JH, Hegedus L, et al. Thyrotropin receptor antibodies and Graves’ disease, a side-effect of 131Ⅰ treatment in patients with nontoxic goiter. J Clin Endocrinol Metab, 1997, 82(9):2926-2930.
8 Nygaard B, Faber J, Veie A, et al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131Ⅰ therapy.Thyroid, 1999, 9(5):477-481.
9 Weiss M, Gorges R, Hirsch C, et al. Incidence of immunogenic hyperthyroidism after radioiodine therapy of focal thyroid gland autonomy. Results of a multicenter study. Med Klin (Munich), 1999,94(5):239-244.
10 Giovanella L, Ceriani L, C, arancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies(TRAb) in autoimmune thyroid diseases. Q J Nucl Med, 2001, 45(1):115-119.
11 Rapoport B, McLachlan S M. Thyroid autoimmunity. J Clin Invest, 2001, 108(9):1253-1259.
12 Custro N, Ganci A, Scafidi V, et al. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter:relat-ion to thyroid autoimmunjty. J Endocrinol Invest, 2003, 26(2):106-110.
13 Pedersen IB, Knudsen N, Jorgensen T, et al. Thyroid peroxidase and thyroglobin autoanfibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxt),2003, 58(1):36-42.
14 Hollower JG, Staehling NW, Flanders WD, et al. Serum thyrotropin, thyrox-ine and thyroid antibodies in the United States population (1988-1994):NHANES IL J Clin Endocrinol Metab,2002, 87(2):489-499.
15 Hirsch C, Spyra JL, Langhammer HR, et al. Occurrence of immune hyperthyroidism after radioiodine therapy of autonomous goiter.Med Klin (Munich), 1997, 92(3):130-137.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[3]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[6]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[7]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[8]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[11]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[12]汤建林,李玉莹,高柳艳,等.131I治疗Graves病规范化建设体会[J].国际放射医学核医学杂志,2011,35(3):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.Standardization of 131I therapy for Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
[13]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[14]卢建林,侯建全,杨永青.125I-脱氧尿苷治疗膀胱癌的实验与临床研究[J].国际放射医学核医学杂志,2009,33(3):154.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
LU Jian-lin,HOU Jian-quan,YANG Yong-qin.Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):154.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
[15]阎军艳,李险峰.放射治疗在晚期甲状腺乳头状癌中的研究进展[J].国际放射医学核医学杂志,2017,41(1):59.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
Yan Junyan,Li Xianfeng.Role of radiation therapy in the treatment of advanced papillary thyroid carcinoma and its research progress[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):59.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
[16]张志祥,郑岚,罗加,等.131I治疗Graves病伴白细胞减少的临床研究[J].国际放射医学核医学杂志,2008,32(4):230.
ZHANG Zhi-xiang,ZHENG Lan,LUO Jia,et al.Clinical study on 131I therapy Graves disease complicated with peripheral blood leukcytopenia[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):230.
[17]林琛,王鲁华,李俊雄,等.131Ⅰ治疗Graves’甲状腺亢进症伴白细胞减少前后血清和尿中β2-微球蛋白变化分析[J].国际放射医学核医学杂志,2007,31(2):98.
LIN Chen,WANG Lu-hua,LI Jun-xiong,et al.Changes of serum and urine β2-microglobulin of leukopenia in hyperthyroidism of Graves’ disease before and after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):98.
[18]崔丽群,张承刚,李玲玲.小剂量131I治疗青少年Graves’病85例患者疗效观察[J].国际放射医学核医学杂志,2007,31(4):226.
CUI Li-qun,ZHANG Cheng-gang,LI Ling-ling.The observation of curative effects by therapy with low-dose 131I in younger with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):226.
[19]陆克义,李险峰,段炼,等.Graves’病患者131Ⅰ治疗后对其周围人群辐射当量剂量的评估[J].国际放射医学核医学杂志,2006,30(6):347.
LU Ke-yi,LI Xian-feng,DUAN Lian,et al.Evaluation of the dose equivalent from patients with Graves’ disease after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):347.
[20]秦岚,邵梦麟,王俊起.小剂量131I治疗甲亢的对比研究[J].国际放射医学核医学杂志,2005,29(3):112.
QIN lan,SHAO Meng-lin,WANG Jun-qi.Comparative study of low dose 131I treatment in patients with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(6):112.